PRME241115P5000
- 1.05
- +0.10+10.53%
Prime Medicine Newsroom
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings
Morgan Stanley Maintains Prime Medicine(PRME.US) With Hold Rating, Cuts Target Price to $5
Bristol-Myers Squibb (BMY.US) collaborates with Prime Medicine (PRME.US) to develop innovative cell therapy.
Prime Medicine will receive an upfront payment of $55 million and $55 million in private equity, and is eligible to receive over $3.5 billion in milestone payments.
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $10
Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Prime Medicine's Strategic Alliances and Growth Potential Affirm Buy Rating
Prime Medicine Analyst Ratings
BMO Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $19
A Quick Look at Today's Ratings for Prime Medicine(PRME.US), With a Forecast Between $10 to $19
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
Buy Rating Reaffirmed for Prime Medicine on Strong Cash Position and Promising Technology Platforms
U.S. stock market anomaly | Prime Medicine soared about 45%, signed a research collaboration and license agreement with bristol-myers squibb.
September 30th, Gelonghui | Prime Medicine (PRME.US) surged by about 45%, reaching a peak of $5.02. On the news front, Prime Medicine signed a research collaboration and licensing agreement with Bristol-Myers Squibb, agreeing to jointly develop and commercialize multiple therapies. According to the agreement, Bristol-Myers Squibb will invest $55 million to purchase Prime's equity, and Prime will receive a $55 million upfront payment. Once certain sales and development milestones are reached, the upfront payment could exceed $3.5 billion.
Strategic Focus and BMY Collaboration Bolster Prime Medicine's Financial Outlook: Hold Rating Affirmed
Prime Medicine, Inc. (PRME) Gets a Hold From Stifel Nicolaus
Sector Update: Health Care Stocks Steady Premarket Monday
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Ahead of Powell's Speech on Economic Outlook
Traders Consolidate Positions in Final Session for Q3, Driving Cautious Losses for US Equity Futures
Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb
Sector Update: Health Care
Market-Moving News for September 30th